 system treatment advanc recurr endometri carcinoma current statu futur direct multipl system therapi patient endometri cancer progestin standard initi treatment metastat diseas past year effect patient sever larg trial benefit adjuv set altern agent tamoxifen modest activ few studi combin activ drug doxorubicin cisplatin activ cytotox agent current random studi combin drug single-ag doxorubicin effect drug hematopoiet growth factor altern hormon cytotox agent sound scientif rational effect treatment option patient